This narrative review examines how socioeconomic disparities accelerate health decline in older adults. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
In FFS, AD incidence (2008-2018) decreased (138 to 104); MCI incidence increased (8 to 47), but the sum (MCI + AD) was relatively stable (146 to 151). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The incidence and prevalence of dementia are increasing. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Linear regression models showed that higher community deprivation on the ADI was associated with greater WMH volume, independently of age, sex, years of education, smoking, and time between study visits (beta=0.11, p =.028). 4 key findings →
Participants: 388 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found declining dementia incidence but increasing dementia prevalence in a sample that includes the vast majority of older adults in the United States. 3 key findings →
Participants: 1,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
41/100
Age-related hearing loss (ARHL) has emerged as a significant and potentially modifiable risk factor for neurodegenerative disorders, including Alzheimer's disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Statins show mixed results in CKD and ESRD, with limited benefits in reducing cardiovascular events in dialysis patients. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
41/100
Hepatocellular carcinoma (HCC) remains a major global health burden, ranking as one of the leading causes of cancer-related deaths worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is becoming a major public health problem in Sub-Saharan Africa (SSA), with prevalence increasing due to demographic transitions, increasing life expectancy, and increasing prevalence of non-communicable diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cardiovascular disease (CVD) and cancer remain the leading causes of mortality in the United States, where poor diet has surpassed smoking as the leading risk factor for death, and life expectancy has hit a plateau as CVD mortality has stagnated over the past decade. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent advances in dementia research have expanded our understanding of modifiable risk factors, with air pollution being a well-established contributor. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hypertension remains a leading modifiable risk factor for cardiovascular and renal conditions and dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Many medical and epidemiological studies use multivariable regression to test whether several independent variables (exposures) are causal determinants of a health outcome. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Delirium, a severe neuropsychiatric syndrome characterised by acute deficits in attention and self-awareness, is common among elderly inpatients, with incidence increasing with age and prolonged hospitalisation. 2 key findings →
Participants: 89 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Compared with stage 0 CKM syndrome, stages 3 and 4 were significantly associated with an increased risk of dementia (hazard ratio [HR], 1.35; 95% confidence interval [CI], 1.14-1.59; HR, 1.80; 95% CI 1.57-2.07). 5 key findings →
Participants: 389,287 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
41/100
Higher intakes of total sugar (HR = 1.292, 95 % CI = 1.148--1.453) and free sugar intake (HR = 1.254, 95 % CI = 1.117--1.408) were significantly associated with increased dementia risk. 4 key findings →
Participants: 172,516 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
During a median follow-up of 14.1 years, 279 early-onset dementia cases and 3167 late-onset dementia cases were documented. 5 key findings →
Participants: 249 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Obesity and its associated metabolic disturbances increase the risk of cognitive decline, dementia, and anxiety-related disorders. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repetitive head impact (RHI) exposure. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive training appears effective in improving cognitive functions and delaying cognitive decline in people at risk of Alzheimer's disease but requires more standardized research for conclusive evidence. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
Higher education was associated with lower vascular risk (p < 0.001) and WMH burden (p = 0.004). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Neighborhood deprivation was associated with poorer cognition (r = 0.36, p < 0.001), greater prevalence of modifiable risk factors (r = 0.36, p < 0.001), and greater SVD burden (β = 0.18, p = 0.008). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
all-cause mortality, stroke recurrence, cognition, and C-reactive protein (CRP). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In the overall cohort (28 403 risperidone users and 136 324 mtatched controls), risperidone was associated with increased risk of stroke (adjusted hazard ratio: 1.28; 95% CI: 1.20-1.37). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 195 participants, 33% had dementia after 3 years of follow-up. 5 key findings →
Participants: 195 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Association of Midlife Plasma Amyloid-β Levels With Cognitive Impairment in Late Life: The ARIC Neurocognitive Study
- Computer-based cognitive training for older adults: Determinants of adherence
- Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer’s Disease and Type 2 Diabetes
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
- Effects of air pollution on human health and practical measures for prevention in Iran
- Diabetes, Prediabetes, and Brain Aging: The Role of Healthy Lifestyle
- Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy
- Mediterranean and MIND Diets Containing Olive Biophenols Reduces the Prevalence of Alzheimer's Disease
- Risk factors and screening instruments to predict adverse outcomes for undifferentiated older emergency department patients: a systematic review and meta-analysis
- Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →